BPC-157 is the most-searched research peptide and one of the least-studied in people. Its side-effect record therefore has to be read in two parts: what the few published human studies recorded, and what people and clinicians have since reported to FDA. This page sets out both, with sources and dates, and says what neither can tell you. It reports; it is neither reassurance nor a warning, and where a decision is involved, the person to make it with is a clinician. What dose figures circulate, and where they come from, is on our BPC-157 dosage page. How brands appear on this site is set out on our disclosure page.
Everyone who has received BPC-157 in a published study
FDA's reviewers evaluated BPC-157 for the agency's Pharmacy Compounding Advisory Committee, which met on July 23–24, 2026 (FDA briefing document, BPC-157-related bulk drug substances, evaluation dated 2026-05-11). Searching PubMed and Embase, they found five clinical studies. Together they are the whole published human record:
| Study | Who | What they received | Adverse events reported |
|---|---|---|---|
| Veljaca 2002 and 2003 (meeting abstracts) | 24 healthy volunteers | Up to 2 mg/kg by enema, daily for 8 days | Most frequent: headache and flatulence |
| Ruenzi 2005 (meeting abstract) | 53 randomised with ulcerative colitis, about half on BPC-157 | 80 mg enema daily for 2 weeks | 3 withdrawn for an adverse event on BPC-157, 2 on placebo — "mainly progression of UC" |
| Lee and Padgett 2021 | 17 with knee pain (16 followed up), retrospective chart review | 2–4 mg into the knee, 1–2 injections, some with thymosin β4 | None described |
| Lee, Walker and Ayadi 2024 | 12 women with interstitial cystitis | 10 mg injected into the bladder wall, once | "No adverse events were reported" |
| Lee and Burgess 2025 | 2 volunteers, both previously given IV BPC-157 | 10 mg IV on day 1, 20 mg on day 2 | None; no change in heart, liver, kidney, thyroid or glucose tests |
That is roughly 80 people, the longest exposure two weeks. FDA's summary: "No serious adverse events appear to have been reported with these studies. However, these studies were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature, and the authors provided limited information on safety data." Safety monitoring, it added, was unclear for most of them.
Two further points about that record are ours, from reading the abstracts. All three published injection studies share one first author, Edwin Lee, one journal (Alternative Therapies in Health and Medicine) and a private-clinic setting in Florida; none had a control group. And the intravenous study's two participants had both received IV BPC-157 before, which selects people who already tolerated it. Neither point makes the studies wrong; both limit how far a finding of "no adverse events" can travel.
The route that matters most has no human data at all. FDA found "no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal" routes. Subcutaneous injection is the route every clinic and vendor page describes.
What the animal studies flagged
The animal literature is often summarised as showing no toxicity. FDA's reviewers read the one published toxicology package more closely. In 28-day intramuscular studies in rats and dogs they noted "clinically relevant safety signals": clotting times shortened in rats and prolonged in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels. No study longer than 28 days was identified to show whether those findings reproduce or whether others emerge, and no carcinogenicity study exists. The same package reported BPC-157 was not mutagenic and caused no birth defects in pregnant rats given it by injection; FDA noted that this does not cover the full reproductive cycle.
What FDA's adverse-event database holds
FDA's own search, through December 4, 2025, retrieved three reports where BPC-157 was a suspect product: nine days of redness and swelling at the injection site (alongside compounded thymosin); shortness of breath leading to an emergency visit, with no further detail; and diffuse skin darkening and gum darkening after a research-labelled BPC-157/TB-500 blend, which stopped when the product was stopped and returned, identically, when it was taken again. FDA judged that reaction likely product-related, but because the vial held two peptides it could not assign it to BPC-157.
We ran the same database on 2026-09-25 for "BPC 157" or "BPC157" in any product name. It returned 20 reports, received from 2021 to 2026:
| Reports | |
|---|---|
| BPC-157 coded as a suspect drug | 9 |
| BPC-157 coded only as a concomitant drug | 11 |
| Received in 2026 | 8 |
| Flagged serious | 16 |
| Involving hospitalisation | 7 |
| Recording a death | 0 |
The three suspect reports FDA counted are the three received before its cutoff, so the two counts agree; the rest arrived afterwards or name BPC-157 only alongside something else. Of the six suspect reports received since, two stand out:
- FAERS 26455240 (received 2026-02-26): a 44-year-old woman; BPC-157 is the only product named. Coded reactions: hives, facial swelling, redness, abdominal pain and shortness of breath, flagged life-threatening. The report also codes "no reaction on previous exposure", meaning earlier doses had not produced it. A reaction that appears only after earlier uneventful doses is the kind of event FDA's reviewers had in mind when they raised immunogenicity (below); one report cannot show that is what happened.
- FAERS 26725788 (received 2026-05-06): a seizure, in a man using BPC-157 with bacteriostatic water and three unapproved over-the-counter products; the coded terms include product contamination and sterility issues. Too many products to attribute.
The others name BPC-157 inside multi-product regimens (with sermorelin, thymosin β4 and semaglutide in one; with CJC-1295 in another) or code quality complaints — "product label issue", "suspected product quality issue". Across all 20, the most frequent single term is still "drug ineffective", as our peptide side effects page found in its own count.
A database like this can only hold what someone files. FDA's footnote gives part of the reason the number is small: 503A compounders "generally do not report adverse events to FDA", and research-labelled vials have no manufacturer obliged to. Twenty reports is a statement about reporting, not a safety rate.
The risk FDA could not measure
The part of FDA's review that applies to every injected vial is not in any study. A peptide injected under the skin can provoke antibodies — "the consequences of triggering an immune response may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions" — and the risk rises with aggregates and synthesis impurities in the product. FDA wrote that BPC-157 "may pose a significant risk for immunogenicity" by injection or nasal spray, that no study has investigated it, and that it also judged BPC-157 not well characterised as a substance, citing missing data on impurities, aggregates, bioburden and endotoxin. Those are properties of a particular vial, not of the molecule, which is why what a lab report does and does not show matters more for this compound than any figure on this page.
What is being run now
A ClinicalTrials.gov search on 2026-09-25 returned four BPC-157 records: a 42-person oral safety and pharmacokinetic trial in Mexico from 2015 whose status has been unknown for years and which never posted results (NCT02637284); a 120-person hamstring-strain trial recruiting since February 2026 (NCT07437547); a 30-person rotator-cuff surgery trial due to start in January 2027 (NCT07803250); and a completed 40-person study of peptide gummies (NCT07752381). None has posted results. The hamstring trial, if it reports, would be the first registered, controlled record of repeated BPC-157 injection with a posted adverse-event table.
What the record does not contain
Any human study of subcutaneous, oral or nasal BPC-157; any exposure longer than two weeks; any controlled injection study; any measurement of antibodies to it; any animal toxicity study longer than 28 days, or any carcinogenicity study; and any analysis connecting reported reactions to what was actually in the vial. It is also prohibited at all times in sport under the World Anti-Doping Agency's list. Its neighbour in the Wolverine blend, TB-500, has its own and differently shaped record, and the approval-and-compounding context for both is on our peptide therapy explainer. Anyone deciding whether to use BPC-157, or whether a symptom is related to it, should take that question to a clinician.
Sources and dates
Read 2026-09-25: FDA briefing document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026 (evaluation dated 2026-05-11) — nonclinical toxicology, human safety, immunogenicity and conclusion sections; PubMed abstracts for PMIDs 34324435, 39325560 and 40131143; FAERS via the openFDA drug event endpoint ("BPC 157" or "BPC157", 20 reports, each read for suspect/concomitant coding, reactions and seriousness); ClinicalTrials.gov API v2 for "BPC-157", "BPC 157" and "Bepecin" (4 records). The Veljaca and Ruenzi abstracts are meeting abstracts not indexed in PubMed; they are reported here as FDA's reviewers describe them. Corrections go to the contact page.